Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hetero Drugs Ltd.

www.heterodrugs.com

Latest From Hetero Drugs Ltd.

Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US

A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July. 

Coronavirus COVID-19 Pricing Strategies

Zydus Cadila Plans Indian Remdesivir Entry In July

Zydus Cadila hopes to launch its version of Gilead’s remdesivir by end-July in India, even as earlier licensees Hetero Drugs and Cipla have just commercialized the antiviral. Plans for pegylated interferon alfa-2b to treat COVID-19 include a trial in Mexico and an IND in the US. Separately, desidustat is being considered for additional indications.

Strategy Generic Drugs

Remdesivir Rivals Hit Indian Market

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Coronavirus COVID-19 Generic Drugs

Is Dexamethasone The Next Hydroxychloroquine For India?

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations.

Coronavirus COVID-19 India
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Hetero Drugs Ltd.
  • Senior Management
  • Bandi Parthasaradhi Reddy, Managing Dir.
  • Contact Info
  • Hetero Drugs Ltd.
    Phone: (91) 40 23704923
    7-2-A2, Hetero Corporate
    Industrial Est.
    Sanath Nagar, 500 018
    India
UsernamePublicRestriction

Register